RxDoctor Payments Data

Rajjit Abrol, MD

Clinical Cardiac Electrophysiology · Plano, TXNPI 1164530739

Payments from drug & device makers

$19,969in general payments, 2019–2025

Across 327 payments — averaging $61.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$12K
  • Abbott$2K
  • Biosense Webster, Inc.$1K
  • Boston Scientific$813
  • Johnson & Johnson$711
  • Impulse Dynamics (USA) Inc.$385
  • plus $2K from 32 others

What the payments were for

  • Speaking & faculty fees$4,37522%
  • Travel & lodging$2,62413%
  • Food & beverage$12,97065%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,969 in reported general payments places this provider in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

See all clinical cardiac electrophysiology providers in Texas

Medicare billing

Part B allowed, 2024
$546,430
Medicare patients
996
Services billed
7,246

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$230,319
XareltoRivaroxaban162$164,144
Dofetilide126$25,736
SotalolSotalol Hcl319$5,981
Metoprolol Succinate259$3,770
Flecainide Acetate102$3,203
Acebutolol Hcl30$1,808
Amiodarone Hcl158$1,606
Pindolol15$1,151
Furosemide103$583
Torsemide35$525
Warfarin Sodium39$518
ClopidogrelClopidogrel Bisulfate51$509
Cephalexin79$483
Midodrine Hcl16$441

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$125$230,319221 claims
Johnson & JohnsonXarelto$711$164,144162 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 233 clinical cardiac electrophysiology providers in Texas.

Other clinical cardiac electrophysiology in Plano

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →